



Billing and Coding Guide

Coverage

Medicare covers JEVTANA under the Medicare Part B benefit. In most cases, JEVTANA claims will be processed by Part A/B Medicare Administrative Contractors (MACs) (for physician office and hospital sites of service), Carriers (physician office) or Fiscal Intermediaries (hospitals). Medicare Advantage plans will most likely cover JEVTANA under a medical benefit.

Medicaid and private payers will likely cover JEVTANA under the medical benefit, as they do other physician administered products, but there are some scenarios where this may not always be the case.

Product Codes

JEVTANA may be identified by a Healthcare Common Procedure Coding System (HCPCS) Level II code, National Drug Code (NDC), and a Current Procedural Terminology (CPT) code.

HCPCS Level II codes include J-codes and C-codes. The following codes should be utilized for billing:

HCPCS Level II Codes			
		Physician Office	Most Payers
J9043	Injection, cabazitaxel, 1mg	Hospital Outpatient	Most non-Medicare payers
C9276	Injection, cabazitaxel, 1mg	Hospital Inpatient	Most payers
		Hospital Outpatient	Medicare

National Drug Code (NDC)	
0024-5824-11	JEVTANA is supplied as a kit containing one single-use vial of 60 mg/1.5 mL JEVTANA Injection and one vial of diluent for JEVTANA (13% (w/w) ethanol in water for injection). Both items are in a blister pack in one carton.

CPT Code	
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

INDICATION

JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

Neutropenia: Neutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. JEVTANA is contraindicated in patients with neutrophil counts of $\leq 1,500$ cells/mm³. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.

Severe hypersensitivity: Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

Please see next page for additional Important Safety Information and accompanying full [Prescribing Information](#), including **Boxed WARNING**.

IMPORTANT SAFETY INFORMATION, (continued)

CONTRAINDICATIONS

J EVTANA is contraindicated in patients with neutrophil counts of $\leq 1,500/\text{mm}^3$, patients with a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80, and patients with severe hepatic impairment (total bilirubin $>3\times$ upper limit of normal (ULN)).

WARNINGS AND PRECAUTIONS

Bone Marrow Suppression (BMS): BMS manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur. Neutropenic deaths have been reported. Monitor blood counts frequently to determine if initiation of G-CSF and/or dosage modification is needed. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Monitoring of complete blood counts is essential on a weekly basis during cycle 1 and before each treatment cycle thereafter so that the dose can be adjusted, if needed. Caution is recommended in patients with hemoglobin <10 g/dl.

Increased Toxicities in Elderly Patients: Patients ≥ 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia. Monitor closely.

Hypersensitivity Reactions: Severe hypersensitivity reactions can occur. Premedicate all patients with antihistamines, corticosteroids and H₂ antagonists prior to J EVTANA. Observe patients closely, especially during the first and second infusions. Discontinue J EVTANA immediately if severe hypersensitivity occurs and treat as indicated.

Gastrointestinal (GI) Adverse Reactions: Nausea, vomiting, and severe diarrhea may occur. Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trials and mortality related to diarrhea has been reported. Intensive measures may be required for severe diarrhea and electrolyte imbalance. Rehydrate and treat with antiemetics and antidiarrheals as needed. If experiencing grade ≥ 3 diarrhea, dosage should be modified.

GI hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported. Risk may be increased with neutropenia, age, steroid use, concomitant use of NSAIDs, antiplatelet therapy or anticoagulants, and prior history of pelvic radiotherapy, adhesions, ulceration and GI bleeding. Abdominal pain and tenderness, fever, persistent constipation, diarrhea, with or without neutropenia, may be early manifestations of serious GI toxicity and should be evaluated and treated promptly. J EVTANA treatment delay or discontinuation may be necessary.

Renal Failure: Cases, including those with fatal outcomes, have been reported. Identify cause and manage aggressively.

Urinary Disorders including Cystitis: Cystitis, radiation cystitis, and hematuria, including that requiring hospitalization, has been reported with J EVTANA in patients who previously received pelvic radiation. Cystitis from radiation recall may occur late in treatment with J EVTANA. Monitor patients who previously received pelvic radiation for signs and symptoms of cystitis while on J EVTANA. Interrupt or discontinue J EVTANA in patients experiencing severe hemorrhagic cystitis. Medical and/or surgical supportive treatment may be required to treat severe hemorrhagic cystitis.

Respiratory Disorders: Interstitial pneumonia/pneumonitis, interstitial lung disease and acute respiratory distress syndrome have been reported and may be associated with fatal outcome. Patients with underlying lung disease may be at higher risk for these events. Acute respiratory distress syndrome may occur in the setting of infection. Interrupt J EVTANA if new or worsening pulmonary symptoms develop. Closely monitor, promptly investigate, and appropriately treat patients receiving J EVTANA. Consider discontinuation. The benefit of resuming J EVTANA treatment must be carefully evaluated.

Use in Patients with Hepatic Impairment: J EVTANA dose should be reduced for patients with mild (total bilirubin >1 to $\leq 1.5 \times$ ULN or AST $>1.5 \times$ ULN) and moderate (total bilirubin >1.5 to $\leq 3.0 \times$ ULN and any AST) hepatic impairment, based on tolerability data in these patients. Administer J EVTANA 20 mg/m² for mild hepatic impairment. Administer J EVTANA 15 mg/m² for moderate hepatic impairment. Monitor closely.

Embryo-Fetal Toxicity: J EVTANA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of J EVTANA.

ADVERSE REACTIONS (ARs)

The most common all grades adverse reactions and laboratory abnormalities ($\geq 10\%$) with J EVTANA 20 mg/m² or 25 mg/m² are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.

DRUG INTERACTIONS

Avoid coadministration of J EVTANA with strong CYP3A inhibitors. If patients require coadministration of a strong CYP3A inhibitor, consider a 25% J EVTANA dose reduction.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** The safety and efficacy of J EVTANA have not been established in females. There are no human data on the use of J EVTANA in pregnant women to inform the drug-associated risk.
- **Lactation:** The safety and efficacy of J EVTANA have not been established in females. There is no information available on the presence of J EVTANA in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.
- **Females and Males of Reproductive Potential:** Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of J EVTANA.

Please see accompanying full Prescribing Information, including Boxed WARNING.